BioPartner UK appoints Strategic Communications Specialist Dr Priya Kalia to Advisory Board
BioPartner UK, the independent, accredited trade organisation, announces the appointment of Dr Priya Kalia, Managing Director of SciTribe Ltd, to its Advisory Board. BioPartner UK’s Advisory Board includes senior investors, executive and non-executive directors, and business development executives. It is focused on driving awareness of global opportunities for small-to-medium enterprises and…
Maxion Therapeutics welcomes Dr Arndt Schottelius as new CEO
Maxion Therapeutics, the biotechnology company developing antibody-based drugs for previously untreatable ion channel- and GPCR-driven diseases, announces that Dr Arndt Schottelius has been appointed as the new Chief Executive Officer, effective on 1 March 2024, to take the Company to its next phase of development. The appointment is part of a planned succession process, with co-founder Dr John…
Fundraising extension to >£20m for Eagle Genomics and appointment of new leadership
Eagle Genomics is pleased to announce it has raised additional financing of £3 million (USD $4 million) to further deploy its pioneering software platform that enables corporate customers to explore and monetize on microbiome-related research. The current funding brings Eagle’s total capital raising to over £20 million (USD $25 million) over the last 12 months. Together with this fundraising, the…
Ion channel drug developer Maxion Therapeutics appoints Eva-Lotta Allan as Chair of its Board of Directors
Maxion Therapeutics (“Maxion”), the biotechnology company developing antibody-based drugs for previously untreatable ion channel- and GPCR-driven diseases, announced the appointment of senior industry leader Eva-Lotta Allan as the Chair of its Board of Directors. The announcement comes at an important moment of growth by the company as it advances its lead programme towards the clinic, following…
Maxion Therapeutics awarded £2 million Innovate UK funding to develop ion channel antibodies for “hard-to-treat" autoimmune diseases
Biotechnology company Maxion Therapeutics announces it has been awarded a prestigious GBP £2 million grant from Innovate UK, as part of its
ICRISAT and Eagle Genomics partnership to accelerate microbiome-based solutions to drive global climate resilience, sustainable food systems and improved nutrition
ICRISAT and Eagle Genomics sign Memorandum of Understanding
Maxion Therapeutics announces the completion of its USD $16 million Series A financing
The funds will be used to support the development of novel biologics targeting ion channels and G-protein-coupled receptors (GPCRs) via Maxion’s KnotBody® platform.